SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status.
Fujihara KM, Corrales Benitez M, Cabalag CS, Zhang BZ, Ko HS, Liu DS, Simpson KJ, Haupt Y, Lipton L, Haupt S, Phillips WA, Clemons NJ.
Fujihara KM, et al. Among authors: cabalag cs.
Mol Cancer Ther. 2021 Oct;20(10):1858-1867. doi: 10.1158/1535-7163.MCT-21-0067. Epub 2021 Jul 26.
Mol Cancer Ther. 2021.
PMID: 34315763
Clinical Trial.